Therefore, in a cross-sectional study, we investigated the occurrence of CD4+ CD161+ T-cells in SAP, newly diagnosed, treatment-naïve RA patients at baseline and at 3 and 6 months after start of methotrexate (MTX) treatment. This evidence concerns the gene CD4 and rheumatoid arthritis.